Share on LinkedInShare on LinkedIn

ARTICLE · 03 MARCH 2025

Why one expert is preferred over another, despite similar qualifications

Expert evidence should be logical, consistent and well-reasoned in order to be compelling.

AustraliaLitigation, Mediation & Arbitration

Sun Pharma ANZ Pty Ltd v Otsuka Pharmaceutical Co Ltd [2025] FCA 44

Background

Otsuka Pharmaceutical Co. Ltd holds Australian Patent No. 2004285448 for a controlled-release injectable aripiprazole formulation used in treating schizophrenia and bipolar disorder. In August 2014, Otsuka sought a patent extension based on two products containing aripiprazole listed on the Australian Register of Therapeutic Goods (ARTG). However, IP Australia initially rejected the request, citing that aripiprazole had already been included in the ARTG for an earlier product (ABILIFY tablets). After further correspondence, Otsuka's request was granted, extending the patent's expiration to 25 July 2029.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from